About Us
A Differentiated Approach to Target and Drug Discovery
We are a pioneering clinical-stage biotechnology company committed to the development of innovative therapeutics for immune-mediated inflammatory diseases (IMIDs) using the power of artificial intelligence (AI) and machine learning (ML). Our focus lies in identifying novel targets and drugs by decoding the intricate mechanisms and pathways that drive the initiation and progression of inflammation in patients with debilitating IMIDs such as atopic dermatitis (AD), indolent systemic mastocytosis (ISM), and eosinophilic esophagitis (EoE).
Our Vision
- We aim to expedite the process of target and drug discovery, with the ultimate goal of providing medicines that allow rapid control of inflammation, prevent tissue damage, improve the quality of life, and achieve long-term disease remission for patients suffering from IMIDs. We leverage technologies such as AI and ML to elp navigate the complex biological associations and unlock novel therapeutic approaches for treating chromnic inflammation.
Addressing Unmet Medical Needs
IMIDs represent a diverse group of conditions characterized by common inflammatory pathways, and they present an urgent need for safe, efficacious, and long-term oral therapies. Through our innovative strategy, we integrate AI and ML analyses with the expertise of domain specialists to identify targets, understand their association with symptomatology across the IMIDs spectrum, and uncover potential therapeutics that can effectively impact chronic inflammation.
Our Future Endeavors
We recognize the substantial burden imposed by dermatologic and gastrointestinal disorders on patients’ lives, healthcare systems, and the economy. While conventional therapies like corticosteroids are commonly used, their limitations and associated adverse events call for more selective and effective treatments. Our goal is to develop novel oral small molecule therapies that precisely target inflammation, addressing the root cause of IMIDs and promoting improved outcomes for patients.
We were spun out by InveniAI, our parent, in 2021 and are headquartered in Guilford, Connecticut.
Meet our team
Krishnan Nandabalan, Ph.D.
Chairman, President & CEO
Salvatore Alesci, M.D., Ph.D.
Chief Scientific Officer
Steve Okada, M.D.
Chief Medical Officer
Aman Kant
Chief Business Officer
Michael Aiello, CPA
Chief Financial Officer
Sheryl Bauer, Ph.D.
SVP, Technical Operations and Quality
Sameer Sharma, Ph.D
SVP and Head of Translational Research
Patricia Spera, Ph.D
VP Clinical Development and Operations
Glenn Kanner, Ph.D
VP, Program Management
Anita Ganjoo, Ph.D
VP, External Communications
Krishnan Nandabalan, Ph.D.
Chairman, President & CEO
Salvatore Alesci, M.D., Ph.D.
Chief Scientific Officer
Steve Okada, M.D.
Chief Medical Officer
Aman Kant
Chief Business Officer
Michael Aiello, CPA
Chief Financial Officer
Sheryl Bauer, Ph.D.
SVP, Technical Operations and Quality
Sameer Sharma, Ph.D
SVP and Head of Translational Research
Patricia Spera, Ph.D
VP Clinical Development and Operations
Glenn Kanner, Ph.D
VP, Program Management
Anita Ganjoo, Ph.D.
VP, External Communications
Krishnan Nandabalan, Ph.D.
Chairman of Board
Invea Therapeutics
Demetrios Kydonieus, MBA
President
R-Pharm
Jonathan Zalevsky, Ph.D.
SVP, Research & CSO
Nektar Therapeutics
Kerrie Brady, MBA, MS
CEO
OcuTerra
Jason Fenton
Head of Healthcare Capital Markets
Oppenheimer & Co. Inc.
Krishnan Nandabalan, Ph.D.
Chairman of Board
Invea Therapeutics
Demetrios Kydonieus, MBA
President
R-Pharm
Jonathan Zalevsky, Ph.D.
SVP, Research & CSO
Nektar Therapeutics
Kerrie Brady, MBA, MS
CEO
OcuTerra
Jason Fenton
Head of Healthcare Capital Markets
Oppenheimer & Co. Inc.
